Be part of the knowledge.™

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

3148

LikeLikedUnlike

31-45 of 919

It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
It Takes a Village, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
- David Eichenbaum, MD
  Peer
0.25 credits
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CE
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
- Jennifer R. Brown, MD, PhD
  Peer
0.25 credits
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CE
Double-Class Refractory CLL in Community Practice: Current and Future Management
- John C. Byrd, MD
  Peer
0.25 credits
Personalizing First-Line Therapy for CLL
CME/CE
Personalizing First-Line Therapy for CLL
- William Wierda, MD, PhD
  Peer
- Matthew S. Davids, MD, MMSc
  Peer
0.25 credits
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
CME/CE
Missing the Window in Ambulatory Patients With HFrEF on GDMT: Strategies for CV Risk Reduction
- Stephen J. Greene, MD, FACC, FHFSA
  Peer
- Gianluigi Savarese, MD
  Peer
0.25 credits
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CE
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
- Charles E. Geyer Jr., MD, FACP
  Peer
- Komal Jhaveri, MD, FACP
  Peer
0.25 credits
advertisement
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
  Peer
- Cristina Rodriguez, MD
  Peer
0.50 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
- María-Victoria Mateos, MD, PhD
  Peer
- Luciano Costa, M.D., Ph.D.
  Peer
0.25 credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 credits 8 episodes
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
advertisement
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
- Kathryn Arbour
  Peer
0.75 program credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended